Download PDF
Thromb Haemost 1975; 33(01): 107-112
DOI: 10.1055/s-0038-1647820
Meeting of the International Committee on Thrombosis and Haemostasis — Symposium on Heparin, Basel, Switzerland, September, 1974
Schattauer GmbH

A Case against Heparin Therapy of Intravascular Coagulation[*]

P. W Straub
1   Department of Medicine, Kantonsspital, University of Zurich, Switzerland
› Author Affiliations
Further Information

Publication History

Publication Date:
02 July 2018 (online)

    Permissions and Reprints

Summary

Administration of a potentially dangerous drug like heparin should not be based on theoretical considerations and innumerable case reports but 1) on a firm diagnosis and 2) on a critical evaluation of the clinical benefit.

The validity of criteria for the diagnosis of intravascular coagulation (IC) is discussed. It is emphasized in particular that loss of fibrinogen into extravascular spaces can only be excluded by assays of the level and disappearance rate of serum proteins not subject to the proteolytic action of thrombin or plasmin.

Even when the diagnosis can be reasonably established, heparin therapy in a particular condition should only be advocated if its clinical benefit has been demonstrated in controlled clinical trials.

Our conviction that heparin has as yet a small if any place in the management of patients with so-called intravascular coagulations is based mainly on two sets of arguments, one stemming from a critique of the diagnosis of IC, the other from a general attitude in the evaluation of therapeutic procedures.

* Presented at the Symposium on Heparin, Basel, Switzerland, September, 1974.


 

  • References

  • 1 Benz J. J. Clotting factors and fibrinogen split products in the extravascular space. Thrombosis et Diathesis Haemorrhagica 1968; 19: 226
    PubMedGoogle Scholar
  • 2 Bleyl U, Kuhn W, Graeff H. Retikuloendotheliale Clearance intravasaler Fibrinmonomere in der Milz. Thrombosis et Diathesis Haemorrhagica 1969; 22: 87
    PubMedGoogle Scholar
  • 3 Charm S. E, Wong B. L. Shear degradation of fibrinogen in the circulation. Science 1970; 170: 466
    CrossrefPubMedGoogle Scholar
  • 4 Clawson C, White J. G. Platelet interaction with bacteria. II. Fate of the bacteria. American Journal of Pathology 1971; 65: 381
    PubMedGoogle Scholar
  • 5 Cohen P, Gardner F. H. Thrombocytopenia, a laboratory sign and complication of Gram-negative bacteremic infection. Archives of Internal Medicine 1966; 117: 113
    CrossrefPubMedGoogle Scholar
  • 6 Fletcher A. P, Biederman O, Moore D, Alkjaersig N, Sherry S. Abnormal plasminogen plasmin system activity (fibrinolysis) in patients with hepatic cirrhosis: its cause and consequences. Journal of Clinical Investigation 1964; 43: 681
    CrossrefPubMedGoogle Scholar
  • 7 Gazzard B. G, Clark R, Borirakchanyavat V, Williams R. A controlled trial of heparin therapy in the coagulation defect of paracetamol-induced hepatic necrosis. Gut 1974; 15: 89
    CrossrefPubMedGoogle Scholar
  • 8 Gmür J, Ganzoni N, Straub P. W. Observations on blood coagulation, fibrinolysis and hemolysis in severe burns. XIIIth International Congress of Hematology, Munich, August 2-8 1970 Abstract vol. p. 107 1970;
    PubMedGoogle Scholar
  • 9 Herold R, Meier W. E, Straub P. W. Surface accumulation and reduced survival of I125-fibrinogen during wound healing. Helvetica medica Acta 1973; 37: 55
    PubMedGoogle Scholar
  • 10 Herold R, Straub P. W. Acute hepatic necrosis of hepatitis and mushroom poisoning. The value of coagulation tests in their differentiation, prognostic assessment and pathogenesis. Helvetica medica Acta 1973; 37: 5
    PubMedGoogle Scholar
  • 11 Hillenbrand P, Parbhoo S. P, Jedrychowski A, Sherlock S. Significance of intravascular coagulation and fibrinolysis in acute hepatic failure. Gut 1974; 15: 83
    CrossrefPubMedGoogle Scholar
  • 12 Kolodié L, Rachail M, Seigneurin D. Dosage des produits de dégradation de la fibrine (P.D.F.) dans le sérum au cours des cirrhoses du foie. Lyon Médical 1973; 229: 671
    PubMedGoogle Scholar
  • 13 Lee L. Reticuloendothelial clearance of circulating fibrin in the pathogenesis of the generalized Shwartzman reaction. Journal of Experimental Medicine 1962; 115: 1065
    CrossrefPubMedGoogle Scholar
  • 14 Lewis J. H, Szeto Z. F. Clearance of infused fibrin. Federation Proceedings 1965; 24: 840
    PubMedGoogle Scholar
  • 15 Lewis J. H, Szeto I. L. F, Curiel D. G. Leukofibrinolysis. Blood 1972; 40: 844
    PubMedGoogle Scholar
  • 16 Post R. M, Desforges J. F. Thrombocytopenic effect of ethanol infusion. Blood 1968; 31: 344
    PubMedGoogle Scholar
  • 17 Rake M. O, Flute P. T, Shilkin K. B, Lewis M. L, Winch J, Williams R. Early and intensive therapy of intravascular coagulation in acute liver failure. Lancet II: 1215 1971;
    PubMedGoogle Scholar
  • 18 Riedler G. F, Straub P. W, Frick P. G. Thrombocytopenia in septicemia. A clinical study for the evaluation of its incidence and diagnostic value. Helvetica medica Acta 1972; 36: 23
    PubMedGoogle Scholar
  • 19 Sherman L. A, Fletcher A.P, Sherry S. In vivo transformation between fibrinogens of varying ethanol solubilities : A pathway of fibrinogen catabolism. Journal of Laboratory and Clinical Medicine 1969; 73: 574
    PubMedGoogle Scholar
  • 20 Straub P. W, Frick P. G. The coagulation disorder in promyelocytic leukemia. Helvetica medica Acta 1967; 34: 44
    PubMedGoogle Scholar
  • 21 Straub P. W. Chronic intravascular coagulation. Clinical spectrum and diagnostic criteria, with special emphasis on metabolism, distribution and localization of I131- fibrinogen. Acta medica Scandinavica Suppl. 526 1971;
    PubMedGoogle Scholar
  • 22 Straub P. W. Chronic intravascular coagulation: Localized or generalized? With evidence for thrombus turnover. Thrombosis et Diathesis Haemorrhagica Suppl. 1973; 56: 1
    PubMedGoogle Scholar